Herpes simplex virus type 1 infection in mice with severe combined immunodeficiency (SCID)
- PMID: 2850780
- DOI: 10.1007/BF01319810
Herpes simplex virus type 1 infection in mice with severe combined immunodeficiency (SCID)
Abstract
Herpes simplex virus type 1 (HSV-1) infection in mutant mice with severe combined immunodeficiency (SCID mice), i.e., mice in which the differentiation of both T and B lymphocytes is severely impaired, was studied. All control (infected and not treated with antibodies or with immune spleen cells) SCID mice were dead by 17 days after intracutaneous injection in the right midflank with 1 x 10(5) PFU of a virulent HSV-1 strain, Hayashida. Immunization with an avirulent strain of HSV-1 (SKa) did not protect them from death or prolong the survival time. Tissue virus titration of infected mice killed at various times after inoculation detected infectious virus in various organs, dorsal root ganglia, spinal cord, brain, kidney and adrenal gland in addition to the inoculation site of the skin in SCID mice, whereas virus could be detected only in the inoculation site and the nervous tissues in euthymic BALB/c mice, and in the adrenal gland from only one out of 17 nude mice. Human gamma globulin containing neutralizing antibody against HSV-1 prolonged the survival time but did not protect SCID mice from death. Transfer of spleen cells from immunized BALB/c mice protected the infected SCID mice from death. Treatment of spleen cells with anti-Thy 1.2 monoclonal antibody and complement abolished the protection.
Similar articles
-
Herpes simplex virus type 1 infection in mice with severe combined immunodeficiency (SCID).Adv Exp Med Biol. 1990;278:191-7. doi: 10.1007/978-1-4684-5853-4_19. Adv Exp Med Biol. 1990. PMID: 1705079 No abstract available.
-
Dissemination of herpes simplex virus in nude mice after intracutaneous inoculation and effect of antibody on the course of infection.J Gen Virol. 1982 Dec;63(2):475-9. doi: 10.1099/0022-1317-63-2-475. J Gen Virol. 1982. PMID: 6296289
-
Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.Infect Immun. 1981 Oct;34(1):192-9. doi: 10.1128/iai.34.1.192-199.1981. Infect Immun. 1981. PMID: 6271681 Free PMC article.
-
Passive immunotherapy for encephalitis caused by herpes simplex virus.Rev Infect Dis. 1986 Jul-Aug;8 Suppl 4:S439-45. doi: 10.1093/clinids/8.supplement_4.s439. Rev Infect Dis. 1986. PMID: 3018895 Review.
-
The mouse model and understanding immunity to herpes simplex virus.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S935-45. doi: 10.1093/clind/13.supplement_11.s935. Rev Infect Dis. 1991. PMID: 1664131 Review.
Cited by
-
Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells.J Virol. 1991 Nov;65(11):6008-14. doi: 10.1128/JVI.65.11.6008-6014.1991. J Virol. 1991. PMID: 1920624 Free PMC article.
-
Both CD4+ and CD8+ T cells are involved in protection against HSV-1 induced corneal scarring.Br J Ophthalmol. 2000 Apr;84(4):408-12. doi: 10.1136/bjo.84.4.408. Br J Ophthalmol. 2000. PMID: 10729300 Free PMC article.
-
Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts.J Virol. 2000 Nov;74(21):9813-7. doi: 10.1128/jvi.74.21.9813-9817.2000. J Virol. 2000. PMID: 11024107 Free PMC article. Review. No abstract available.
-
A severe combined immunodeficient (SCID) mouse model for infection with Entamoeba histolytica.J Exp Med. 1992 Dec 1;176(6):1605-9. doi: 10.1084/jem.176.6.1605. J Exp Med. 1992. PMID: 1460420 Free PMC article.
-
Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.J Virol. 2011 Feb;85(4):1793-803. doi: 10.1128/JVI.01924-10. Epub 2010 Dec 1. J Virol. 2011. PMID: 21123390 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical